These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37582270)

  • 1. Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation.
    Venkatesh S; Richardson M
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):622-630. PubMed ID: 37582270
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits.
    Zhou T; Miao Y; Li Z; Lu P; Liang Z; Yang J; He J; Xia H; Zhang Z; Zhang J
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):522-528. PubMed ID: 32310714
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles.
    Halder A; Khopade AJ
    Curr Eye Res; 2021 Jul; 46(7):1031-1037. PubMed ID: 33719796
    [No Abstract]   [Full Text] [Related]  

  • 5. Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops.
    Inoue D; Mohamed YH; Uematsu M; Kitaoka T
    Cutan Ocul Toxicol; 2020 Jun; 39(2):158-164. PubMed ID: 32295438
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system.
    Ryan G; Fain JM; Lovelace C; Gelotte KM
    BMC Ophthalmol; 2011 Apr; 11():8. PubMed ID: 21510881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
    Kahook MY; Noecker RJ
    Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study.
    Tau J; Passerini MS; Del Papa M; Aguilar A; Berra A
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1941-1946. PubMed ID: 35015115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
    Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
    Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
    Liang H; Baudouin C; Pauly A; Brignole-Baudouin F
    Br J Ophthalmol; 2008 Sep; 92(9):1275-82. PubMed ID: 18723745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
    Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
    Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
    J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation.
    Pauly A; Roubeix C; Liang H; Brignole-Baudouin F; Baudouin C
    Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8172-80. PubMed ID: 23150620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of In Vitro Corneal Permeation and In Vivo Ocular Bioavailability in Rabbits of Three Marketed Latanoprost Formulations.
    Chauchat L; Guerin C; Kaluzhny Y; Renard JP
    Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):633-645. PubMed ID: 37682463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride.
    Whitson JT; Cavanagh HD; Lakshman N; Petroll WM
    Adv Ther; 2006; 23(5):663-71. PubMed ID: 17142200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
    Ammar DA; Noecker RJ; Kahook MY
    Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
    Kahook MY; Noecker R
    Adv Ther; 2008 Aug; 25(8):743-51. PubMed ID: 18670744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.